OPTIMAPHARM Obtains CZECH MKS Research

Following the league of leading in the markets of  clinical research organizations, Optimapharm obtained Czech CRO company MKS research. Following the acquisition , Optimapharm will foray into the  Czech Market thereby bolstering it sportfolio of clients in the pharmaceutical and biotech industries therefore surging  its market position in Central Europe.

Optimapharm CEO Gordana Gregurić Čičak said “The clinical research market is experiencing a continued rise, and we have the knowhow, references and strong financial position enabling us to lead the consolidation in the region. Moreover, our ambition is to double our revenues over the next three years, and continue acquiring good-quality companies such as MKS Research.”

Optimapharm is headquartered in Zagreb, Croatia, and has offices in more than ten European countries. It covers markets with over 200 million people and has the expertise to conduct phase I – IV clinical research across Europe and through partners in the U.S.